Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor

[Image: see text] SMYD3 has been implicated in a range of cancers; however, until now no potent selective small molecule inhibitors have been available for target validation studies. A novel oxindole series of SMYD3 inhibitors was identified through screening of the Epizyme proprietary histone methy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ACS Med Chem Lett
Main Authors: Mitchell, Lorna H., Boriack-Sjodin, P. Ann, Smith, Sherri, Thomenius, Michael, Rioux, Nathalie, Munchhof, Michael, Mills, James E., Klaus, Christine, Totman, Jennifer, Riera, Thomas V., Raimondi, Alejandra, Jacques, Suzanne L., West, Kip, Foley, Megan, Waters, Nigel J., Kuntz, Kevin W., Wigle, Tim J., Scott, Margaret Porter, Copeland, Robert A., Smith, Jesse J., Chesworth, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2015
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4753551/
https://ncbi.nlm.nih.gov/pubmed/26985287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.5b00272
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados